Want to see NVNO full AI Analyst Report?
Top Page
enVVeno Medical
(NASDAQ:NVNO)
Select Model
Select Model
Rating:42Neutral
Price Target:
$7.50
▼(-34.61% Downside)
Action:Reiterated
Date:10/01/26
NVNO scores low primarily due to pre-revenue operations, ongoing losses, and persistent cash burn that imply continued external funding needs and dilution risk. Technicals also weigh on the score with a clear downtrend (below major moving averages and negative MACD), though oversold RSI slightly offsets near-term risk. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Focused medical-device platform
A focused product addressing severe chronic venous insufficiency gives enVVeno a clearly defined clinical and commercial objective. If VenoValve demonstrates durable clinical value, this specialization could support differentiated positioning in a targeted vascular intervention market.
Negative Factors
Pre-revenue business model
With no reported revenue, the company has not yet demonstrated commercial adoption or a recurring source of operating income. This leaves future financial performance highly dependent on successful VenoValve development, regulatory progress, and eventual market acceptance.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused medical-device platform
A focused product addressing severe chronic venous insufficiency gives enVVeno a clearly defined clinical and commercial objective. If VenoValve demonstrates durable clinical value, this specialization could support differentiated positioning in a targeted vascular intervention market.
Read all positive factors
enVVeno Medical (NVNO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.66M
Dividend YieldN/A
Average Volume (3M)26.21K
Price to Earnings (P/E)―
Beta (1Y)1.83
Revenue GrowthN/A
EPS Growth43.06%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-520.08
Shares Outstanding694,826
10 Day Avg. Volume28,141
30 Day Avg. Volume26,209
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-2.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit58.21
Enterprise Value/Ebitda0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-16.19
Revenue Forecast (FY)N/A
enVVeno Medical Business Overview & Revenue Model
Company Description
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutio...
enVVeno Medical Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -237.00K | 0.00 | -528.00K | -546.00K | -525.00K | -452.91K |
| EBITDA | -15.55M | -18.98M | -21.29M | -22.97M | -24.14M | -16.07M |
| Net Income | -15.72M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M |
Balance Sheet | ||||||
| Total Assets | 22.66M | 29.56M | 44.95M | 48.63M | 41.66M | 57.70M |
| Cash, Cash Equivalents and Short-Term Investments | 21.49M | 28.21M | 43.15M | 46.41M | 39.04M | 54.73M |
| Total Debt | 505.00K | 700.00K | 1.06M | 1.40M | 1.72M | 2.01M |
| Total Liabilities | 1.99M | 2.43M | 2.79M | 2.44M | 2.93M | 3.29M |
| Stockholders Equity | 20.67M | 27.13M | 42.16M | 46.20M | 38.73M | 54.40M |
Cash Flow | ||||||
| Free Cash Flow | -14.62M | -15.57M | -16.88M | -18.89M | -15.73M | -12.22M |
| Operating Cash Flow | -14.62M | -15.57M | -16.84M | -18.86M | -15.62M | -11.85M |
| Investing Cash Flow | 14.27M | 15.86M | 1.33M | -7.87M | -34.55M | -368.00K |
| Financing Cash Flow | 1.15M | 1.02M | 13.64M | 25.79M | 0.00 | 57.61M |
enVVeno Medical Technical Analysis
Negative
11.47
Price Trends
9.97
Negative
10.32
Negative
10.65
Negative
Market Momentum
-0.52
Negative
39.26
Neutral
35.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVNO, the sentiment is Negative. The current price of 11.47 is above the 20-day moving average (MA) of 8.60, above the 50-day MA of 9.97, and above the 200-day MA of 10.65, indicating a bearish trend. The MACD of -0.52 indicates Negative momentum. The RSI at 39.26 is Neutral, neither overbought nor oversold. The STOCH value of 35.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVNO.
enVVeno Medical Risk Analysis
enVVeno Medical disclosed 36 risk factors in its most recent earnings report. enVVeno Medical reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The Company received a not-approvable letter from the FDA. Q4, 2025
enVVeno Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $16.10M | -0.39 | -565.55% | ― | -28.53% | 47.55% | |
46 Neutral | $8.01M | -0.06 | -547.15% | ― | 80.25% | 77.34% | |
45 Neutral | $11.31M | -0.62 | -445.14% | ― | 8.64% | -61.01% | |
45 Neutral | $21.51M | -0.16 | -33.51% | ― | -89.02% | -107.75% | |
42 Neutral | $5.66M | -0.02 | -62.28% | ― | ― | 43.06% | |
42 Neutral | $50.42M | -0.97 | 1719.71% | ― | -6.76% | 42.70% |
* Healthcare Sector Average
NVNO
enVVeno Medical
8.15
-19.18
-70.18%
SINT
Sintx Technologies
2.13
-2.08
-49.41%
CTSO
Cytosorbents
3.59
-14.85
-80.53%
PAVM
PAVmed
2.69
-13.46
-83.34%
COCH
Envoy Medical
0.65
-0.27
-29.08%
TNON
Tenon Medical, Inc.
2.98
-39.72
-93.02%
enVVeno Medical Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
enVVeno Medical Updates Investors With New Presentation
Neutral
Jul 15, 2026
On July 14, 2026, enVVeno Medical Corporation released a new investor presentation intended for use in meetings with investors, analysts, and other stakeholders. The materials were furnished via a Form 8-K filing, explicitly designated as not R...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.